Bone Cancer News
-
CD BioSciences Announces Comprehensive Range of Nervous System Tissue Microarrays
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological ...
-
CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material
CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on ...
By CELLINK
-
HK inno.N licenses in mAbxience’s denosumab biosimilar
HK inno.N said it has signed an exclusive license agreement with Spain’s mAbxience to market the latter’s Prolia (ingredient: denosumab) biosimilar, a preventive treatment for osteoporosis and cancer-related skeletal complications, in Korea. Under the contract, HK inno.N will exclusively market two types of denosumab biosimilars – 60 mg and 120 mg — from mAbxience, and ...
By mAbxience
-
MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study – a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis – are expected to be available in early 2024. The company previously ...
By MorphoSys AG
-
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
Data from the MANIFEST trial show durable improvements in both spleen volume and symptom score beyond 24 weeks with pelabresib in combination with ruxolitinib for JAK inhibitor-naïve patients An exploratory analysis of biomarkers from the MANIFEST trial indicates the potential for disease modification MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ...
By MorphoSys AG
-
Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of Wide-Field Optical Coherence Tomography (WF-OCT) in Head and Neck Surgeries
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) announced the publication of a peer-reviewed research article in JAMA Otolaryngology—Head and Neck Surgery. The study’s findings validate the further exploration of the use of Perimeter’s wide-field Optical Coherence Tomography (WF-OCT) technology to ...
-
First Completion of a Full Treatment Workflow in the First European Hospital-Based BNCT Facility
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world's leading provider of control systems for the planet's most complex machines, today announced that they have reached their second joint milestone in the clinical commissioning of Neutron ...
-
Aurora BioPharma to Attend Pioneers 2017 at the Mandarin Oriental Hotel in New York
Aurora BioPharma, Inc., a clinical stage biotechnology company developing a breakthrough in cancer treatment, announced today that company CEO and President, Robert Brooks, will attend Pioneers 2017 presented by Joseph Gunnar & Co., LLC taking place Tuesday May 2nd at the Mandarin Oriental Hotel in New York. About Joseph Gunnar & Co., LLC Joseph Gunnar & Co., LLC was founded in 1997 ...
-
Aurora BioPharma To Join In On A Presentation And Discussion On The GBM AGILE Trial At The Ritz-Carlton, Pentagon City
Aurora BioPharma, Inc., a clinical stage biotechnology company developing a breakthrough in cancer treatment, announced today that company CEO and President, Robert Brooks, will join in on a presentation and discussion of the GBM AGILE (Adaptive, Global, Innovative, Learning Environment) trial. The meeting is being held at the Ritz Carlton, at Fashion Centre at Pentagon City, April 11th. About ...
-
A Guide to Dental Oral Surgeries
Oral surgeons have the skillset and the technology to transform their patients’ mouths. From relatively simple tasks like removing impacted teeth to life-saving measures like removing oral cancer, these highly skilled professionals are trained to rescue their patients in their time of need. There’s more than one way to get your teeth worked on. Dental surgeries come in many ...
-
Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021. Poster ...
-
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference
The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference in Denver, Colorado. During the conference, the Prostate Snap Oral I scientific session included two abstracts that were presented by The Cesium Advisory ...
By Isoray Inc.
-
Creative Diagnostics Launches Measles Virus Antigens for the Detection of Antibodies
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for bio-technology industry, recently announced the release of new measles virus antigens suitable for both IgM and IgG detection. These new products are intended for research use only and are not diagnostic use. Measles virus (MeV) is a negative-sense RNA virus with a non-segmented genome and lipid envelope ...
-
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapy Phase 2 to proceed with alternating 2-vector therapy in combination with pembrolizumab, which will help inform the randomized Phase 2 trial with pembrolizumab planned to start in the first half of 2023 Additional Phase 2 cohort will ...
-
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The ...
By Transgene
-
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 development plans in head and neck cancers HOOKIPA ...
-
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis ...
-
Galera Announces Plan to Submit Avasopasem NDA by Year End
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced its intent to file a New Drug Application (NDA) for avasopasem manganese (avasopasem) for the treatment of radiotherapy-induced severe oral mucositis ...
-
First Simulated Patient Treatment Carried Out in the First Hospital-Based BNCT Facility in Europe
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world’s leading provider of control systems for the planet’s most complex machines, today announced that Neutron Therapeutics' nuBeam® BNCT System, using Cosylab's OncologyOne ...
-
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
No Grade 4 or 5 esophagitis in patients treated with avasopasem Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced topline results from the six-week, Phase 2a, open-label, single-arm AESOP trial of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you